← Back to Search

Unknown

AZD4831 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, day 2 to day 8 and day 14
Awards & highlights

Summary

This trial tests a new drug called AZD4831 in two different versions to see how well each is absorbed by the body. Healthy volunteers will take each version of the drug at different times. Researchers will measure how much of the drug enters the bloodstream to determine which version is better absorbed. AZD4831 is being developed as a potential treatment for heart failure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, day 2 to day 8 and day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, day 2 to day 8 and day 14 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Area under plasma concentration-time curve from zero to infinity (AUCinf)
Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)
Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)
+6 more
Secondary study objectives
Number of participants with Adverse Events (AEs)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Sequence 2 (Formulation B + Formulation A)Experimental Treatment1 Intervention
Participants will receive a single oral dose of Treatment 2: Formulation B followed by a washout period of at least 14 days from first dose of AZD4831. After the washout period, participants will receive a single oral dose of Treatment 1 Formulation A.
Group II: Sequence 1 (Formulation A + Formulation B)Experimental Treatment1 Intervention
Participants will receive a single oral dose of Treatment 1: Formulation A followed by a washout period of at least 14 days from first dose of AZD4831. After the washout period, participants will receive a single oral dose of Treatment 2: AZD4831 Formulation B.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AZD4831
2022
Completed Phase 3
~990

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,352 Previous Clinical Trials
288,646,779 Total Patients Enrolled
ParexelIndustry Sponsor
308 Previous Clinical Trials
101,121 Total Patients Enrolled
~10 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top